Texas Heart Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Houston TX United States (1962)

Organization Overview

First Clinical Trial
2006
NCT00313339
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)

Active Ingredients

Drugs in Phase 3 Trials (3)

pomegranate (1 trial)

red blood cells (1 trial)

vm202 (2 trials)

Drugs in Phase 2 Trials (2)

autologous mesenchymal stem cells (1 trial)

rosuvastatin (crestor) (1 trial)

Drugs in Phase 1 Trials (2)

bone marrow derived autologous cd34+ selected cells (1 trial)

stem cells (1 trial)

Drugs in Other Trials (2)

clenbuterol (1 trial)

d-ribose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Common Cold (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Headache (Phase 3)

Heart Failure (Phase 2)

Infarction (Phase 1)

Inflammation (Phase 2)

Influenza, Human (Phase 3)

Ischemia (Phase 2)

Myocardial Infarction (Phase 1)

Myocardial Ischemia (Phase 2)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 9